The Theoreo team recently took part in the "Evolution of Cancer Pharmacology" conference, a prestigious event organized by the Italian Society of Pharmacology (SIF) at the Grand Hotel Salerno on March 15th and 16th. During this engaging conference, participants delved into the revolution of cancer pharmacology, from preclinical research to clinical studies. The discussions highlighted the significant progress made in the treatment of oncological diseases over the past decades, thanks to the introduction of targeted therapies and immunotherapies. These advancements have been made possible through continuous research in the field of personalized medicine. The Theoreo team was thrilled to be part of this transformation and grateful for the opportunity to contribute to the ongoing evolution of research in this crucial area of medicine.
Among the contributions from Theoreo were three presentations: "A Metabolomic Approach Enhanced by Machine Learning for Colorectal Cancer Screening"; "Advancing Male Uro-genital Cancer Screening with Metabolomic Profiling and Ensemble Machine Learning"; and "Metabolomic Profiling for Non-Invasive Ovarian Cancer Screening." These works demonstrate the team's commitment to leveraging cutting-edge techniques, such as metabolomics and machine learning, to improve cancer screening and diagnosis, ultimately aiming to enhance patient outcomes in the fight against cancer.
Among the contributions from Theoreo were three presentations: "A Metabolomic Approach Enhanced by Machine Learning for Colorectal Cancer Screening"; "Advancing Male Uro-genital Cancer Screening with Metabolomic Profiling and Ensemble Machine Learning"; and "Metabolomic Profiling for Non-Invasive Ovarian Cancer Screening." These works demonstrate the team's commitment to leveraging cutting-edge techniques, such as metabolomics and machine learning, to improve cancer screening and diagnosis, ultimately aiming to enhance patient outcomes in the fight against cancer.